Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Spago Nanomedical AB
SPAGOSpago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Address: ScheelevAegen 22, Lund, Sweden, 223 63
Analytics
Objectif de Cours de WallStreet
10.81 SEKRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés SPAGO
Analyse des dividendes SPAGO
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes SPAGO
Valorisation des titres SPAGO
financières SPAGO
Résultats | 2019 | Dynamique |